← Guangdong Taienkang Pharmaceutical overview

Guangdong Taienkang Pharmaceutical vs Shanghai Fosun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guangdong Taienkang Pharmaceutical Co. Ltd (301263.CS)

Q3 2026
▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

  • Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.

    The profit collapse is the single biggest negative force on the stock this period.

  • New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.

    Two regulatory approvals are concrete new products that can generate future sales.

  • Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.

    These are the main growth catalysts: guaranteed procurement volume plus clinical progress.

  • Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.

    Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

September 2026
▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

  • Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.

    The profit collapse is the single biggest negative force on the stock this period.

  • New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.

    Two regulatory approvals are concrete new products that can generate future sales.

  • Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.

    These are the main growth catalysts: guaranteed procurement volume plus clinical progress.

  • Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.

    Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

Latest
▲3▼1

Profit Collapse Offset by Drug Approvals and Pipeline Progress

  • Interim Profit Plunges 90% First-half 2026 net profit fell 89.97% to 3.72 million yuan on revenue of 320 million yuan, down 7.72%. This weak result is the main drag on the stock, showing core earnings are under heavy pressure despite better cash flow.

    The profit collapse is the single biggest negative force on the stock this period.

  • New Drug Approvals Expand Product Line The subsidiary won registration certificates for labetalol hydrochloride tablets (hypertension) and diquafosol sodium eye drops (dry eye). These add approved products to sell, supporting future revenue, though both face competition and are not immediate profit drivers.

    Two regulatory approvals are concrete new products that can generate future sales.

  • Procurement Win and Pipeline Milestones Baricitinib tablets were selected in the 12th national centralized procurement, guaranteeing hospital sales volume. Separately, cisplatin polymeric micelle won clinical trial approval and CKBA cream showed strong Phase IIa rosacea results, advancing the innovative pipeline.

    These are the main growth catalysts: guaranteed procurement volume plus clinical progress.

  • Buybacks and Cell Therapy Deal Support Sentiment The company repurchased 2.43 million shares for 48.44 million yuan, signaling confidence. It also secured exclusive China promotion rights for an ocular surface cell therapy product, though that deal is a framework arrangement with no near-term earnings impact.

    Buybacks and a strategic partnership are supporting forces, but both are modest in effect.

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.CG)

Q3 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

August 2026
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.

Latest
▲3

Fosun Pharma's innovative drugs drive profit growth and licensing deals

  • Interim profit up 19% on innovative drugs Fosun Pharma's 2026 interim profit rose 19% to RMB 1.144 billion, with innovative drug revenue up 13.84% and overseas revenue up 16.45%. This shows its shift to high-margin drugs is paying off, boosting investor confidence and supporting the stock price.

    This is the core financial result that directly shows improved profitability and validates the growth strategy.

  • Multiple drug approvals and clinical trial greenlights Fosun Pharma received approvals for HLX43 combination therapy trials, GR1803 for multiple myeloma, and a new indication for Luvometinib. These expand its innovative drug pipeline, promising future revenue streams and reinforcing its competitive position.

    These regulatory milestones are new and directly add to the company's growth prospects.

  • Henlius signs $888M licensing deal with Amberstone Henlius licensed two T-cell engager products to Amberstone for up to $888 million in payments. This validates Fosun Pharma's R&D capabilities and brings potential cash inflows, enhancing its financial flexibility and market sentiment.

    This is a new major business development deal that highlights the value of its innovative pipeline.